Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984879 | 0.90 | BRD4 (0.45) | HTTKMT2ABRD4RAB9ANPC1 | |
| SCHEMBL9984119 | 0.89 | BRD4 (0.44) | KMT2ABRD4RAB9ANPC1CYP26A1 | |
| SCHEMBL9984994 | 0.89 | BRD4 (0.43) | GAAKMT2ABRD4RAB9ANPC1 | |
| SCHEMBL9985176 | 0.87 | CYP17A1 (0.43) | KMT2ABRD4RAB9ANPC1CYP26A1 | |
| SCHEMBL9985029 | 0.87 | BRD4 (0.42) | GAAHTTKMT2ABRD4RAB9A | |
| SCHEMBL9985113 | 0.87 | EGFR (0.43) | BRD4RAB9ANPC1CYP26A1CYP19A1 | |
| SCHEMBL9984024 | 0.86 | BRD4 (0.41) | BRD4RAB9ANPC1CYP26A1CYP19A1 | |
| SCHEMBL9984037 | 0.85 | BRD4 (0.41) | KMT2ABRD4RAB9ANPC1CYP26A1 | |
| SCHEMBL9984735 | 0.83 | BRD4 (0.45) | KMT2ABRD4RAB9ACYP26A1MAPT | |
| SCHEMBL9984881 | 0.83 | CYP17A1 (0.48) | GAAKMT2ABRD4MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | claimed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | GAA 2768/4885HTT 4749/4885KMT2A 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.